PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33992954-0 2021 Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Voriconazole 56-68 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-93 33992954-2 2021 Potent inhibition of CYP2B6 was noticeable for some azoles, including voriconazole. Voriconazole 70-82 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 21-27 22232427-7 2012 Inhibition of efavirenz 8-hydroxylation by voriconazole was significantly greater in HLMs with the CYP2B6*6 allele (K(i) = 1.6 +- 0.8 muM) than HLMs with CYP2B6*1/*1 genotype (K(i) = 3.0 +- 1.1 muM). Voriconazole 43-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 154-160 25868557-10 2015 Modeling based on estimated Ki values and plasma concentrations from the literature suggest that the orally administered azoles, particularly ketoconazole and voriconazole, have the greatest potential for inhibiting CYP3A4 pathways, as does voriconazole for the CYP2B6 pathways. Voriconazole 159-171 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 262-268 27600044-0 2016 Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers. Voriconazole 46-58 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 14-33 27600044-3 2016 Efavirenz, a nonnucleoside HIV-1 reverse transcriptase inhibitor, is mainly cleared by CYP2B6, an enzyme strongly inhibited in vitro by voriconazole. Voriconazole 136-148 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 87-93 27600044-4 2016 To test efavirenz metabolism as an in vivo probe of CYP2B6 activity, we quantified the inhibition of CYP2B6 activity by voriconazole in 61 healthy volunteers administered a single 100-mg oral dose of efavirenz with and without voriconazole administration. Voriconazole 120-132 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 27600044-9 2016 This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability. Voriconazole 42-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 179-185 27600044-9 2016 This study demonstrates the mechanisms of voriconazole-efavirenz interaction, establishes the use of a low dose of efavirenz as a safe and selective in vivo probe for phenotyping CYP2B6 activity, and identifies several easy-to-use indices that should enhance understanding of the mechanisms of CYP2B6 interindividual variability. Voriconazole 42-54 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 294-300 22232427-7 2012 Inhibition of efavirenz 8-hydroxylation by voriconazole was significantly greater in HLMs with the CYP2B6*6 allele (K(i) = 1.6 +- 0.8 muM) than HLMs with CYP2B6*1/*1 genotype (K(i) = 3.0 +- 1.1 muM). Voriconazole 43-55 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 99-105 18837430-4 2009 Because of its metabolism by hepatic p450 enzymes, voriconazole may inhibit the clearance of many medications, including vincristine. Voriconazole 51-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 37-41 22190985-5 2009 The pronounced inhibitory impact of voriconazole on methadone metabolism via the cytochrome P450 (CYP)2B6 isoenzyme was identified as a probable cause of the arrhythmia. Voriconazole 36-48 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 81-105 19029318-0 2009 Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Voriconazole 35-47 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 115-128 19029318-5 2009 In pilot experiments, voriconazole showed inhibition of CYP2B6, CYP2C9, CYP2C19, and CYP3A (half-maximal [50%] inhibitory concentrations, <6 microM); its effect on CYP1A2, CYP2A6, CYP2C8, and CYP2D6 was marginal (<25% inhibition at 100 microM voriconazole). Voriconazole 22-34 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 56-62 19029318-6 2009 Further detailed experiments with HLMs showed that voriconazole is a potent competitive inhibitor of CYP2B6 (K(i) < 0.5), CYP2C9 (K(i) = 2.79 microM), and CYP2C19 (K(i) = 5.1 microM). Voriconazole 51-63 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 101-107 19029318-8 2009 Prediction of the in vivo interaction of voriconazole from these in vitro data suggests that voriconazole would substantially increase the exposure of drugs metabolized by CYP2B6, CYP2C9, CYP2C19, and CYP3A. Voriconazole 41-53 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 172-178 19029318-8 2009 Prediction of the in vivo interaction of voriconazole from these in vitro data suggests that voriconazole would substantially increase the exposure of drugs metabolized by CYP2B6, CYP2C9, CYP2C19, and CYP3A. Voriconazole 93-105 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 172-178 17433262-1 2007 Involvement of cytochrome P450 (P450 or CYP) 2C19, 2C9, and 3A4 in N-oxidation of voriconazole, a new triazole antifungal agent, has been demonstrated using human liver microsomes. Voriconazole 82-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 26-30 17433262-1 2007 Involvement of cytochrome P450 (P450 or CYP) 2C19, 2C9, and 3A4 in N-oxidation of voriconazole, a new triazole antifungal agent, has been demonstrated using human liver microsomes. Voriconazole 82-94 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 32-49 17433262-3 2007 Among recombinant P450 isoforms using Escherichia coli expression systems, CYP2C19 and CYP3A4 had voriconazole N-oxidation activities, but not CYP2C9. Voriconazole 98-110 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 18-22